Markets syringe products and related drug-delivery systems to hospitals, clinics, and medical supply organizations. Also holds and stakes Solana as part of its digital-asset treasury strategy.
Sources
10-K for FY2025, filed Mar 31, 2026
Sharps Technology, Inc. is a medical device sales and distribution enterprise focused on the marketing and distribution of syringe products…View ↗
We manage our Treasury Policy under the oversight of our Treasury Oversight Committee. The Treasury Policy establishes the parameters…View ↗
How Do They Make Money?
Customers buy single-use syringe and packaging products, with payment terms following shipment or delivery. The company also earns SOL staking rewards as each staking period ends.
Sources
10-K for FY2025, filed Mar 31, 2026
The Company generates revenue from the sale of single use medical device packaging products, primarily syringe or as packaging components…View ↗
Rewards are recognized as revenue as is earned at the end of each epoch (just under two day periods for SOL). The FMV of the revenue is…View ↗
FY2025
Revenue, FY2025
$204.1K
Sources
10-K for FY2025, filed Mar 31, 2026
Revenue, FY2025: Revenue From Contract With Customer Excluding Assessed Tax
Markets remaining syringe inventory to healthcare providers and organizations and foreign governments, while discussing sales with healthcare companies and distributors.
Sources
10-K for FY2025, filed Mar 31, 2026
Sharps Technology, Inc. is a medical device sales and distribution enterprise focused on the marketing and distribution of syringe products…View ↗
We continue to be in discussions with healthcare companies and distributors for sales of our existing inventory of disposable syringe…View ↗
Jun 1, 2026Company changes its name and shifts focus to an AI-powered finance platform
The company said the platform would serve emerging markets across Asia, Latin America, and Africa.
Sources
8-K, filed Jun 1, 2026
On May 26, 2026, Sharps Technology, Inc., a Nevada corporation (which we refer to both before and after the corporate name change referred…View ↗
May 29, 2026Arthur Levine appointed Chief Financial Officer
Sources
8-K, filed May 29, 2026
On May 22, 2026, SkyAI, Inc., a Nevada corporation (the “Company”) entered into an employment agreement (the “Agreement”) with Arthur…View ↗
Shrinking.
Revenue fell 96% in 3 years, from $5.4M in FY2022 to $204.1K in FY2025, about 66% a year.
From product development to distribution
The older report centered on developing and commercializing safety syringes and planned manufacturing; the latest describes marketing remaining inventory and sourcing future products from third-party manufacturers, after ending research and manufacturing.
Through the Nephron Agreement, Sharps is entering into a manufacturing and supply agreement with InjectEZ regarding the development and…View ↗
10-K for FY2025, filed Mar 31, 2026
Sharps Technology, Inc. is a medical device sales and distribution enterprise focused on the marketing and distribution of syringe products…View ↗
Since our inception in 2017 and through the fourth quarter of 2022, we devoted substantially all of our resources to the research and…View ↗
Added a Solana treasury
The older report focused on syringe products and their commercialization; the latest also describes a treasury centered on SOL, with expected gains from price appreciation and staking rewards.